infectious disease targets

GeneTAG has four patents awarded and three patents pending for seven novel probe systems that can identify gene mutations and gene signatures that are indicative of infectious diseases, drug-resistant subspecies, and mutation driven cancers.

GeneTAG Technology, Inc.

Error-checking DNA Detection Switch probes

Conventional dual-labeled qPCR probes lack error-checking mechanisms and cannot

provide multi-temperature single base discrimination. GeneTAG Technology has

developed 3 error-checking DNA Detection Switch (DDS) probe systems for high-

fidelity detection and/or amplification. DDS probes employ the interaction of 2

labeled polynucleotide components: a fluorescent probe and a quenching antiprobe.

Probes bind preferentially to their intended targets, turning on signaling, while

dissociating from a nearly complementary antiprobe that otherwise turns off

signaling. This general signaling mechanism is termed a ′DNA detection switch′.

DDS probes are designed to match the target sequence, and antiprobes

are complementary to the probe except for a carefully engineered mismatch. The

thermodynamics of this design facilitates exacting target detection because

the competitive antiprobes bind and quench free-floating probes, preventing the

detection of closely related off-targets. Principles and applications of each error-

checking DDS probe system are described below.

Principles of error-checking DDS probes

Internal DNA Detection Switch probes deliver unparalleled specificity

Flip probes can provide quantitative endpoint detection without a qPCR instrument

ZIPR primer-probes for error-checking qPCR amplification

internal DNA Detection Switch probes: high-specificity, error-checking mechanism

About US

Our mission is to provide superior molecular

detection systems that are precise, simple and

inexpensive.

GeneTAG has four patents awarded and three

patents pending for seven

novel probe systems that can identify gene

mutations and gene signatures that are indicative

of infectious diseases, drug-resistant subspecies,

and mutation driven cancers.

1. Murray JL, Hu P, Shafer DA. Seven novel probe

systems for real-time PCR provide absolute single

base discrimination, higher signaling, and generic

components. (2014). J Mol Diagn. 16, 627–638.

2. Storts DR. Alternative Probe-Based Detection

Systems in Quantitative PCR. (2014). J Mol Diagn.

16, 612-614.

OUR MISSION PUBLICATIONS

Contact Us

GeneTAG Technology, Inc.

3781 Presidential Parkway, Suite 9

Atlanta, GA 30340

Phone: 678-805-8840

E-mail: info@genetagtech.com

Website: www.genetagtech.com